Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLBE PCI colchicine trial in coronary artery disease
2023-505028-74-00Phase 3Authorised
- Sponsor
- Ghent University Hospital
- Start
- Jan 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing Colchicine with Placebo (2 arms). Primary endpoint: Primary composite endpoint. Planned start Jan 2024; status: authorised.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2023-505028-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505028-74-00.